Waldenström's Macroglobulinemia
3
Pipeline Programs
3
Companies
2
Clinical Trials
1 recruiting
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
1
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
3100%
+ 1 programs with unclassified modality
On Market (1)
Approved therapies currently available
Competitive Landscape
3 companies ranked by most advanced pipeline stage
BeOne MedicinesCA - San Carlos
2 programsZanubrutinibN/ASmall Molecule1 trial
ZanubrutinibPHASE_4Small Molecule
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
BeiGeneBGB-3111
BeOne MedicinesZanubrutinib
Clinical Trials (2)
Total enrollment: 1,046 patients across 2 trials
A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)
Start: Jan 2017Est. completion: Jun 2022201 patients
Phase 3Completed
Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma
Start: Apr 2022Est. completion: Aug 2028845 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 1,046 patients
Small Molecule is the dominant modality (100% of programs)
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.